People: Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

24 Jan 2020
Change (% chg)

$-0.36 (-7.07%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Vergis, Janet 

Ms. Janet S. Vergis is Independent Director of the Company. She has served on our Board of Directors since the Combination, and previously served on the board of directors of Impax from 2015 until the completion of the Combination. Ms. Vergis has served as an Executive Advisor for private equity firms since January 2013, where she identifies and evaluates healthcare investment opportunities. From January 2011 to August 2012, Ms. Vergis was the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company dedicated to oral health. From 2004 to 2009, she served as President of Janssen Pharmaceuticals LP, McNeil Pediatrics, Inc. and Ortho-McNeil Neurologics, Inc., subsidiaries of Johnson and Johnson (NYSE:JNJ). Ms. Vergis contributed to a number of Johnson & Johnson companies during her 21 years, holding positions of increasing responsibility in research and development, new product development, sales, and marketing. Since May 2014, Ms. Vergis has served as a director on the board of Church & Dwight Co., Inc. (NYSE:CHD), a leading consumer and specialty products company, and is currently a member of the audit and governance committees. She has also served as a director and Chair of the Commercialization Committee for the Board of MedDay Pharmaceuticals, a privately held biotechnology company, since November 2016. Ms. Vergis previously served as a director of Lumara Health, a privately held pharmaceutical company (sold to AMAG Pharmaceuticals) from October 2013 to November 2014, and as a director of OraPharma from January 2011 to June 2012. Ms. Vergis received her MS degree in Physiology and her BS degree in Biology from The Pennsylvania State University.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 91,667
Long-Term Incentive Plans, USD --
All Other, USD 250,000
Fiscal Year Total, USD 341,667

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --